Prevalence and prognostic significance of adrenergic escape during chronic beta-blocker therapy in chronic heart failure. - Wikidata - awgldk - TriplyDB

Prevalence and prognostic significance of adrenergic escape during chronic beta-blocker therapy in chronic heart failure.

Prevalence and prognostic significance of adrenergic escape during chronic beta-blocker therapy in chronic heart failure.

http://www.wikidata.org/entity/Q37091005

about

Ranolazine improves autonomic balance in heart failure when added to guideline-driven therapy.Depression treatment in patients with coronary artery disease: a systematic review.

P2860

Q36641674-EB84CA14-5A5F-4D64-8BAA-6E3F8D647BCC Q37533862-75F091E9-6397-4534-966C-26601AFD6E71

P2860

Prevalence and prognostic significance of adrenergic escape during chronic beta-blocker therapy in chronic heart failure.

http://www.wikidata.org/entity/Q37091005

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on February 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Prevalence and prognostic sign ...... rapy in chronic heart failure.

@en

Prevalence and prognostic sign ...... rapy in chronic heart failure.

@nl

type

label

Prevalence and prognostic sign ...... rapy in chronic heart failure.

@en

Prevalence and prognostic sign ...... rapy in chronic heart failure.

@nl

prefLabel

Prevalence and prognostic sign ...... rapy in chronic heart failure.

@en

Prevalence and prognostic sign ...... rapy in chronic heart failure.

@nl

P1433

Q37091005-D8C9A7C3-7674-4F86-994F-B45F835C63FD

P1476

Q37091005-6FCF6437-29F7-485D-9C85-F5B886C9B732

P2093

Q37091005-3888626A-AEC6-4BE6-A8D6-67A81A3EE05E

Q37091005-511F184B-296A-451B-9C99-BD12840B1AC5

Q37091005-5C172235-26A3-4FA7-A635-688A26B7A44F

Q37091005-7D0A5145-485A-4ED6-8DE1-70FE59B15A86

Q37091005-CD0A3355-F1B0-4A15-99FA-4C9A0C9C9851

Q37091005-D1CB8B15-BBAD-4136-AD0E-3BA6B45F7082

Q37091005-FB98DF57-39B7-4AA8-8CA5-179AD4769FAE

P2860

Q37091005-0ECC493A-0D66-4744-8ACA-56B97AF53A9C

Q37091005-26827A9D-25D2-4B91-872D-75BFAF399E7F

Q37091005-2A17C289-C216-4466-AB37-CC1148C820C1

Q37091005-599514D0-E46B-4E1D-AE57-CF5789F552F3

Q37091005-5DCA9634-B1EC-4FC2-B6DD-7E2B87CA1EE8

Q37091005-6B6BCA07-4CCA-4AEE-930A-54C947EF5AAC

Q37091005-79090A24-4318-4FEF-A438-70C30BC3F888

Q37091005-844F189B-6771-4EC2-9FFD-7C80AADA2DF8

Q37091005-8A69FA04-6894-4BB1-999C-9345B741CAD0

Q37091005-A042B7AF-8DEE-4CE0-B497-39C80307760F

P304

Q37091005-142BFFA6-8716-451F-BAE8-811611FE0510

P31

Q37091005-5B87894D-1B3C-4B84-997D-482612F2851A

P356

Q37091005-1024A817-5A28-40F9-8012-EDB2560B699A

P433

Q37091005-A088F437-962E-43FC-8E65-948E0E5940FA

P478

Q37091005-3FD09255-A266-4E3A-AC8F-C1D8BC66AE6C

P577

Q37091005-4DB34931-FC5B-4B64-BE73-88C4922B8A1F

P5875

Q37091005-7B5147F8-81D8-4094-83E5-869E1FD8471F

P698

Q37091005-AAF24560-9F39-4518-A935-779316821DEC

P921

Q37091005-9208575D-FF23-4CF5-B214-94A580AA806C

P932

Q37091005-1BC2935B-0DEA-4D91-82CF-ABAEB57E5A89

P356

P1433

European Journal of Heart Failure

P1476

Prevalence and prognostic sign ...... rapy in chronic heart failure.

@en

P2093

Andrew Remppis

http://www.w3.org/2001/XMLSchema#string

Christian Zugck

http://www.w3.org/2001/XMLSchema#string

Dieter Schellberg

http://www.w3.org/2001/XMLSchema#string

Hanna Froehlich

http://www.w3.org/2001/XMLSchema#string

Hugo Katus

http://www.w3.org/2001/XMLSchema#string

Lutz Frankenstein

http://www.w3.org/2001/XMLSchema#string

Manfred Nelles

http://www.w3.org/2001/XMLSchema#string

P2860

How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?

A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS.

The clinical implications of aldosterone escape in congestive heart failure.

Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study.

Role of neurohormonal mechanisms in determining survival in patients with severe chronic heart failure.

Aldosterone escape during ACE inhibitor therapy in chronic heart failure.

Relation of aldosterone "escape" despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.

Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart.

Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction.

Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF).

P304

178-184

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/EURJHF/HFN028

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2009-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23938828

http://www.w3.org/2001/XMLSchema#string

P698

19168516

http://www.w3.org/2001/XMLSchema#string

P921

P932

2639421

http://www.w3.org/2001/XMLSchema#string